Climb Bio

Climb Bio Equity

The The Equity of Climb Bio (CLYM) as of Nov 19, 2026 is 160.48 M USD. In the previous year, The Equity was 211.88 M USD — a change of -24.26% (lower).

Equity

160.48 MUSD

YoY

-24.26%

Last updated:

In 2025, Climb Bio's equity was 160.48 M USD, a -24.26% increase from the 211.88 M USD equity in the previous year.

The Climb Bio Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
20.61 M USD
Jan 1, 2020
21.57 M USD
Jan 1, 2021
167.20 M USD
Jan 1, 2022
128.72 M USD
Jan 1, 2023
107.60 M USD
Jan 1, 2024
211.88 M USD
Jan 1, 2025
160.48 M USD
The Climb Bio Equity history
YEAREquityYoY
160.48 MUSD-24.26%
211.88 MUSD+96.92%
107.60 MUSD-16.41%
128.72 MUSD-23.02%
167.20 MUSD+675.24%
21.57 MUSD+4.64%
20.61 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Climb Bio Stock analysis

What does Climb Bio do? Eliem Therapeutics, Inc. develops novel therapies for neuronal excitability disorders, targeting unmet needs in psychiatry, epilepsy, chronic pain, and nervous system disorders. Its lead product ETX-123, a Kv7.2/3 potassium channel opener, is designed to improve safety and tolerability over earlier molecules while leveraging clinically validated mechanisms. The company focuses on validated mechanisms of action with therapeutic potential for patients with these conditions. ETX-123 is a generate new chemical entities candidate that harnesses the efficacy of Kv7.2/3 channel mechanism, with encouraging clinical data in depression, epilepsy, and pain. The company's pipeline includes clinically differentiated product candidates targeting validated therapeutic targets to deliver improved therapeutics. Eliem Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Wilmington, Delaware, with 30 full-time employees. The company's revenue model is not disclosed in the business description, as it is a clinical-stage biotechnology firm focused on research and development rather than commercial product sales. Its primary focus is on advancing its pipeline through clinical trials to achieve regulatory approvals and potential future partnerships or sales. Climb Bio is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Climb Bio's Equity

Climb Bio's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Climb Bio's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Climb Bio's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Climb Bio's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Climb Bio’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Climb Bio stock

The Equity of Climb Bio is 160.48 M USD in 2025.

The Equity of Climb Bio changed from 211.88 M USD to 160.48 M USD, representing a -24.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Climb Bio since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Climb Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Climb Bio

All Key Metrics — Climb Bio